Compile Data Set for Download or QSAR
Report error Found 138 Enz. Inhib. hit(s) with all data for entry = 2172
TargetPeriod circadian protein homolog 2(Human)
Reset Therapeutics

US Patent
LigandPNGBDBM356927(1-(3-(3,6-difluoro- 9H-carbazol-9-yl)-2- hydroxypr...)
Affinity DataEC50:  52nMAssay Description:Compounds were screened by using a high-throughput circadian assay system as previously described in Zhang, E. E. et al. Cell, 2009, 139, 199-210. In...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetPeriod circadian protein homolog 2(Human)
Reset Therapeutics

US Patent
LigandPNGBDBM356720((1R,4S)-2-((R)-3- (3,6-difluoro-9H- carbazol-9-yl)...)
Affinity DataEC50:  54nMAssay Description:Compounds were screened by using a high-throughput circadian assay system as previously described in Zhang, E. E. et al. Cell, 2009, 139, 199-210. In...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetPeriod circadian protein homolog 2(Human)
Reset Therapeutics

US Patent
LigandPNGBDBM356634(1-(3-(9H-carbazol- 9-yl)-2- hydroxypropyl)-3- fluo...)
Affinity DataEC50:  61nMAssay Description:Compounds were screened by using a high-throughput circadian assay system as previously described in Zhang, E. E. et al. Cell, 2009, 139, 199-210. In...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetPeriod circadian protein homolog 2(Human)
Reset Therapeutics

US Patent
LigandPNGBDBM356696(1-(3-(3,6-difluoro- 9H-carbazol-9-yl)-2- hydroxypr...)
Affinity DataEC50:  79nMAssay Description:Compounds were screened by using a high-throughput circadian assay system as previously described in Zhang, E. E. et al. Cell, 2009, 139, 199-210. In...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetPeriod circadian protein homolog 2(Human)
Reset Therapeutics

US Patent
LigandPNGBDBM356724((1R,4S)-2-((R)-3- (9H-carbazol-9-yl)- 2-hydroxypro...)
Affinity DataEC50:  89nMAssay Description:Compounds were screened by using a high-throughput circadian assay system as previously described in Zhang, E. E. et al. Cell, 2009, 139, 199-210. In...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetPeriod circadian protein homolog 2(Human)
Reset Therapeutics

US Patent
LigandPNGBDBM356922((R)-1-((R)-3-(9H- carbazol-9-yl)-2- hydroxypropyl)...)
Affinity DataEC50:  95nMAssay Description:Compounds were screened by using a high-throughput circadian assay system as previously described in Zhang, E. E. et al. Cell, 2009, 139, 199-210. In...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetPeriod circadian protein homolog 2(Human)
Reset Therapeutics

US Patent
LigandPNGBDBM356717(US10214507, Compound 104 | US10759777, Compound 10...)
Affinity DataEC50:  115nMAssay Description:Compounds were screened by using a high-throughput circadian assay system as previously described in Zhang, E. E. et al. Cell, 2009, 139, 199-210. In...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetPeriod circadian protein homolog 2(Human)
Reset Therapeutics

US Patent
LigandPNGBDBM356936((R)-1-((R)-3-(9H- carbazol-9-yl)-2- hydroxypropyl)...)
Affinity DataEC50:  120nMAssay Description:Compounds were screened by using a high-throughput circadian assay system as previously described in Zhang, E. E. et al. Cell, 2009, 139, 199-210. In...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetPeriod circadian protein homolog 2(Human)
Reset Therapeutics

US Patent
LigandPNGBDBM356933(2-(3-(3,6-difluoro- 9H-carbazol-9-yl)-2- hydroxypr...)
Affinity DataEC50:  120nMAssay Description:Compounds were screened by using a high-throughput circadian assay system as previously described in Zhang, E. E. et al. Cell, 2009, 139, 199-210. In...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetPeriod circadian protein homolog 2(Human)
Reset Therapeutics

US Patent
LigandPNGBDBM356658(1-(3-(3,6-difluoro- 9H-carbazol-9-yl)-2- hydroxypr...)
Affinity DataEC50:  120nMAssay Description:Compounds were screened by using a high-throughput circadian assay system as previously described in Zhang, E. E. et al. Cell, 2009, 139, 199-210. In...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetPeriod circadian protein homolog 2(Human)
Reset Therapeutics

US Patent
LigandPNGBDBM356695(1-cyclobutyl-3-(3- (3,6-difluoro-9H- carbazol-9-yl...)
Affinity DataEC50:  129nMAssay Description:Compounds were screened by using a high-throughput circadian assay system as previously described in Zhang, E. E. et al. Cell, 2009, 139, 199-210. In...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetPeriod circadian protein homolog 2(Human)
Reset Therapeutics

US Patent
LigandPNGBDBM356993(1-(3-(9H-carbazol- 9-yl)-2- hydroxypropyl)-3,3- di...)
Affinity DataEC50:  137nMAssay Description:Compounds were screened by using a high-throughput circadian assay system as previously described in Zhang, E. E. et al. Cell, 2009, 139, 199-210. In...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetPeriod circadian protein homolog 2(Human)
Reset Therapeutics

US Patent
LigandPNGBDBM356935(1-(3-(3,6-difluoro- 9H-carbazol-9-yl)-2- hydroxypr...)
Affinity DataEC50:  137nMAssay Description:Compounds were screened by using a high-throughput circadian assay system as previously described in Zhang, E. E. et al. Cell, 2009, 139, 199-210. In...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetPeriod circadian protein homolog 2(Human)
Reset Therapeutics

US Patent
LigandPNGBDBM356666(1-cyclopropyl-3-(3- (3,6-difluoro-9H- carbazol-9-y...)
Affinity DataEC50:  147nMAssay Description:Compounds were screened by using a high-throughput circadian assay system as previously described in Zhang, E. E. et al. Cell, 2009, 139, 199-210. In...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetPeriod circadian protein homolog 2(Human)
Reset Therapeutics

US Patent
LigandPNGBDBM356668(1-(3-(3,6-difluoro- 9H-carbazol-9-yl)-2- hydroxypr...)
Affinity DataEC50:  164nMAssay Description:Compounds were screened by using a high-throughput circadian assay system as previously described in Zhang, E. E. et al. Cell, 2009, 139, 199-210. In...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetPeriod circadian protein homolog 2(Human)
Reset Therapeutics

US Patent
LigandPNGBDBM356645(1-(3-(3,6-difluoro- 9H-carbazol-9-yl)-2- hydroxypr...)
Affinity DataEC50:  171nMAssay Description:Compounds were screened by using a high-throughput circadian assay system as previously described in Zhang, E. E. et al. Cell, 2009, 139, 199-210. In...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetPeriod circadian protein homolog 2(Human)
Reset Therapeutics

US Patent
LigandPNGBDBM356633(1-(3-(9H-carbazol-9-yl)-2-hydroxypropyl)piperidin-...)
Affinity DataEC50:  171nMAssay Description:Compounds were screened by using a high-throughput circadian assay system as previously described in Zhang, E. E. et al. Cell, 2009, 139, 199-210. In...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetPeriod circadian protein homolog 2(Human)
Reset Therapeutics

US Patent
LigandPNGBDBM356962((S)-1-((R)-3-(9H- carbazol-9-yl)-2- hydroxy-2- met...)
Affinity DataEC50:  172nMAssay Description:Compounds were screened by using a high-throughput circadian assay system as previously described in Zhang, E. E. et al. Cell, 2009, 139, 199-210. In...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetPeriod circadian protein homolog 2(Human)
Reset Therapeutics

US Patent
LigandPNGBDBM356938((R)-1-((R)-3-(3,6- difluoro-9H- carbazol-9-yl)-2- ...)
Affinity DataEC50:  184nMAssay Description:Compounds were screened by using a high-throughput circadian assay system as previously described in Zhang, E. E. et al. Cell, 2009, 139, 199-210. In...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetPeriod circadian protein homolog 2(Human)
Reset Therapeutics

US Patent
LigandPNGBDBM356934((S)-1-((R)-3-(9H- carbazol-9-yl)-2- hydroxypropyl)...)
Affinity DataEC50:  188nMAssay Description:Compounds were screened by using a high-throughput circadian assay system as previously described in Zhang, E. E. et al. Cell, 2009, 139, 199-210. In...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetPeriod circadian protein homolog 2(Human)
Reset Therapeutics

US Patent
LigandPNGBDBM356636(US10214507, Compound 71 | US10759777, Compound 71)
Affinity DataEC50:  188nMAssay Description:Compounds were screened by using a high-throughput circadian assay system as previously described in Zhang, E. E. et al. Cell, 2009, 139, 199-210. In...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetPeriod circadian protein homolog 2(Human)
Reset Therapeutics

US Patent
LigandPNGBDBM356640(1-(3-(3,6-difluoro- 9H-carbazol-9-yl)-2- hydroxypr...)
Affinity DataEC50:  192nMAssay Description:Compounds were screened by using a high-throughput circadian assay system as previously described in Zhang, E. E. et al. Cell, 2009, 139, 199-210. In...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetPeriod circadian protein homolog 2(Human)
Reset Therapeutics

US Patent
LigandPNGBDBM356937(3-cyclobutyl-1-(3- (3,6-difluoro-9H- carbazol-9-yl...)
Affinity DataEC50:  204nMAssay Description:Compounds were screened by using a high-throughput circadian assay system as previously described in Zhang, E. E. et al. Cell, 2009, 139, 199-210. In...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetPeriod circadian protein homolog 2(Human)
Reset Therapeutics

US Patent
LigandPNGBDBM356942((R)-1-((R)-3-(9H- carbazol-9-yl)-2- hydroxypropyl)...)
Affinity DataEC50:  210nMAssay Description:Compounds were screened by using a high-throughput circadian assay system as previously described in Zhang, E. E. et al. Cell, 2009, 139, 199-210. In...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetPeriod circadian protein homolog 2(Human)
Reset Therapeutics

US Patent
LigandPNGBDBM356722((1S,4R)-2-((R)-3- (9H-carbazol-9-yl)- 2-hydroxypro...)
Affinity DataEC50:  220nMAssay Description:Compounds were screened by using a high-throughput circadian assay system as previously described in Zhang, E. E. et al. Cell, 2009, 139, 199-210. In...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetPeriod circadian protein homolog 2(Human)
Reset Therapeutics

US Patent
LigandPNGBDBM356721(1-(3-(3,6-difluoro- 9H-carbazol-9-yl)-2- hydroxypr...)
Affinity DataEC50:  224nMAssay Description:Compounds were screened by using a high-throughput circadian assay system as previously described in Zhang, E. E. et al. Cell, 2009, 139, 199-210. In...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetPeriod circadian protein homolog 2(Human)
Reset Therapeutics

US Patent
LigandPNGBDBM356987(1-(3-(9H-carbazol- 9-yl)-2-hydroxy-2- methylpropyl...)
Affinity DataEC50:  225nMAssay Description:Compounds were screened by using a high-throughput circadian assay system as previously described in Zhang, E. E. et al. Cell, 2009, 139, 199-210. In...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetPeriod circadian protein homolog 2(Human)
Reset Therapeutics

US Patent
LigandPNGBDBM356729((R)-1-((R)-3-(3,6- difluoro-9H- carbazol-9-yl)-2- ...)
Affinity DataEC50:  226nMAssay Description:Compounds were screened by using a high-throughput circadian assay system as previously described in Zhang, E. E. et al. Cell, 2009, 139, 199-210. In...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetPeriod circadian protein homolog 2(Human)
Reset Therapeutics

US Patent
LigandPNGBDBM356687(1-(3-(3,6-difluoro- 9H-carbazol-9-yl)-2- hydroxypr...)
Affinity DataEC50:  261nMAssay Description:Compounds were screened by using a high-throughput circadian assay system as previously described in Zhang, E. E. et al. Cell, 2009, 139, 199-210. In...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetPeriod circadian protein homolog 2(Human)
Reset Therapeutics

US Patent
LigandPNGBDBM356944((S)-1-((R)-3-(9H- carbazol-9-yl)-2- hydroxypropyl)...)
Affinity DataEC50:  263nMAssay Description:Compounds were screened by using a high-throughput circadian assay system as previously described in Zhang, E. E. et al. Cell, 2009, 139, 199-210. In...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetPeriod circadian protein homolog 2(Human)
Reset Therapeutics

US Patent
LigandPNGBDBM356939(3-cyclobutyl-1-(3- (3,6-difluoro-9H- carbazol-9-yl...)
Affinity DataEC50:  265nMAssay Description:Compounds were screened by using a high-throughput circadian assay system as previously described in Zhang, E. E. et al. Cell, 2009, 139, 199-210. In...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetPeriod circadian protein homolog 2(Human)
Reset Therapeutics

US Patent
LigandPNGBDBM356705(1-(3-(9H-carbazol- 9-yl)-2- hydroxypropyl)-3- isop...)
Affinity DataEC50:  269nMAssay Description:Compounds were screened by using a high-throughput circadian assay system as previously described in Zhang, E. E. et al. Cell, 2009, 139, 199-210. In...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetPeriod circadian protein homolog 2(Human)
Reset Therapeutics

US Patent
LigandPNGBDBM356976((R)-1-((R)-3-(9H- carbazol-9-yl)-2- hydroxypropyl)...)
Affinity DataEC50:  280nMAssay Description:Compounds were screened by using a high-throughput circadian assay system as previously described in Zhang, E. E. et al. Cell, 2009, 139, 199-210. In...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetPeriod circadian protein homolog 2(Human)
Reset Therapeutics

US Patent
LigandPNGBDBM356643(1-cyclohexyl-3-(3- (3,6-difluoro-9H- carbazol-9-yl...)
Affinity DataEC50:  284nMAssay Description:Compounds were screened by using a high-throughput circadian assay system as previously described in Zhang, E. E. et al. Cell, 2009, 139, 199-210. In...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetPeriod circadian protein homolog 2(Human)
Reset Therapeutics

US Patent
LigandPNGBDBM356714(1-(3-(3,6-difluoro- 9H-carbazol-9-yl)-2- hydroxypr...)
Affinity DataEC50:  286nMAssay Description:Compounds were screened by using a high-throughput circadian assay system as previously described in Zhang, E. E. et al. Cell, 2009, 139, 199-210. In...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetPeriod circadian protein homolog 2(Human)
Reset Therapeutics

US Patent
LigandPNGBDBM356928((R)-1-(3-(3,6- difluoro-9H- carbazol-9-yl)-2- hydr...)
Affinity DataEC50:  287nMAssay Description:Compounds were screened by using a high-throughput circadian assay system as previously described in Zhang, E. E. et al. Cell, 2009, 139, 199-210. In...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetPeriod circadian protein homolog 2(Human)
Reset Therapeutics

US Patent
LigandPNGBDBM356663(1-(3-(3,6-difluoro- 9H-carbazol-9-yl)-2- hydroxypr...)
Affinity DataEC50:  288nMAssay Description:Compounds were screened by using a high-throughput circadian assay system as previously described in Zhang, E. E. et al. Cell, 2009, 139, 199-210. In...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetPeriod circadian protein homolog 2(Human)
Reset Therapeutics

US Patent
LigandPNGBDBM356991(1-(3-(9H-carbazol- 9-yl)-2- hydroxypropyl) pyrroli...)
Affinity DataEC50:  288nMAssay Description:Compounds were screened by using a high-throughput circadian assay system as previously described in Zhang, E. E. et al. Cell, 2009, 139, 199-210. In...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetPeriod circadian protein homolog 2(Human)
Reset Therapeutics

US Patent
LigandPNGBDBM356931(1-(3-(3,6-difluoro- 9H-carbazol-9-yl)-2- hydroxypr...)
Affinity DataEC50:  299nMAssay Description:Compounds were screened by using a high-throughput circadian assay system as previously described in Zhang, E. E. et al. Cell, 2009, 139, 199-210. In...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetPeriod circadian protein homolog 2(Human)
Reset Therapeutics

US Patent
LigandPNGBDBM356638(1-(3-(9H-carbazol- 9-yl)-2- hydroxypropyl) tetrahy...)
Affinity DataEC50:  299nMAssay Description:Compounds were screened by using a high-throughput circadian assay system as previously described in Zhang, E. E. et al. Cell, 2009, 139, 199-210. In...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetPeriod circadian protein homolog 2(Human)
Reset Therapeutics

US Patent
LigandPNGBDBM356653(1-(3-(3,6-difluoro- 9H-carbazol-9-yl)-2- hydroxypr...)
Affinity DataEC50:  300nMAssay Description:Compounds were screened by using a high-throughput circadian assay system as previously described in Zhang, E. E. et al. Cell, 2009, 139, 199-210. In...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetPeriod circadian protein homolog 2(Human)
Reset Therapeutics

US Patent
LigandPNGBDBM356940((S)-1-((R)-3-(3,6- difluoro-9H- carbazol-9-yl)-2- ...)
Affinity DataEC50:  302nMAssay Description:Compounds were screened by using a high-throughput circadian assay system as previously described in Zhang, E. E. et al. Cell, 2009, 139, 199-210. In...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetPeriod circadian protein homolog 2(Human)
Reset Therapeutics

US Patent
LigandPNGBDBM356948((S)-1-((S)-3-(9H- carbazol-9-yl)-2- hydroxy-2- met...)
Affinity DataEC50:  309nMAssay Description:Compounds were screened by using a high-throughput circadian assay system as previously described in Zhang, E. E. et al. Cell, 2009, 139, 199-210. In...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetPeriod circadian protein homolog 2(Human)
Reset Therapeutics

US Patent
LigandPNGBDBM356680(1-cyclohexyl-3-(3- (3,6-difluoro-9H- carbazol-9-yl...)
Affinity DataEC50:  310nMAssay Description:Compounds were screened by using a high-throughput circadian assay system as previously described in Zhang, E. E. et al. Cell, 2009, 139, 199-210. In...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetPeriod circadian protein homolog 2(Human)
Reset Therapeutics

US Patent
LigandPNGBDBM356932((R)-1-((R)-3-(3,6- difluoro-9H- carbazol-9-yl)-2- ...)
Affinity DataEC50:  311nMAssay Description:Compounds were screened by using a high-throughput circadian assay system as previously described in Zhang, E. E. et al. Cell, 2009, 139, 199-210. In...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetPeriod circadian protein homolog 2(Human)
Reset Therapeutics

US Patent
LigandPNGBDBM356946((R)-1-((S)-3-(9H- carbazol-9-yl)-2- hydroxy-2- met...)
Affinity DataEC50:  311nMAssay Description:Compounds were screened by using a high-throughput circadian assay system as previously described in Zhang, E. E. et al. Cell, 2009, 139, 199-210. In...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetPeriod circadian protein homolog 2(Human)
Reset Therapeutics

US Patent
LigandPNGBDBM356703(1-(3-(9H-carbazol- 9-yl)-2- hydroxypropyl)-3- cycl...)
Affinity DataEC50:  315nMAssay Description:Compounds were screened by using a high-throughput circadian assay system as previously described in Zhang, E. E. et al. Cell, 2009, 139, 199-210. In...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetPeriod circadian protein homolog 2(Human)
Reset Therapeutics

US Patent
LigandPNGBDBM356676(1-(3-(3,6-difluoro- 9H-carbazol-9-yl)-2- hydroxy-2...)
Affinity DataEC50:  317nMAssay Description:Compounds were screened by using a high-throughput circadian assay system as previously described in Zhang, E. E. et al. Cell, 2009, 139, 199-210. In...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetPeriod circadian protein homolog 2(Human)
Reset Therapeutics

US Patent
LigandPNGBDBM356669(1-(3-(9H-carbazol- 9-yl)-2- hydroxypropyl)imid- az...)
Affinity DataEC50:  325nMAssay Description:Compounds were screened by using a high-throughput circadian assay system as previously described in Zhang, E. E. et al. Cell, 2009, 139, 199-210. In...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetPeriod circadian protein homolog 2(Human)
Reset Therapeutics

US Patent
LigandPNGBDBM356951(1-(3-(3,6-difluoro- 9H-carbazol-9-yl)-2- hydroxypr...)
Affinity DataEC50:  329nMAssay Description:Compounds were screened by using a high-throughput circadian assay system as previously described in Zhang, E. E. et al. Cell, 2009, 139, 199-210. In...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

Displayed 1 to 50 (of 138 total ) | Next | Last >>
Jump to: